Closed System Drug Transfer Device Market Research Report - Forecast till 2032

Closed System Drug Transfer Device (CSTD) Market Research Report Information By Type (Barrier-Type, Filtration-Type), By Delivery (Closed Bag/Line Access Devices, Closed Vial Access Devices, Closed Syringe Safety Devices) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) ÔÇôMarket Forecast Till 2032

ID: MRFR/HC/6264-CR | 110 Pages | Author: Kinjoll Dey | February 2021         

Closed System Drug Transfer Device Market Speak to Analyst Request a Free Sample

Global Closed System Drug Transfer Device Market Overview


The Closed System Drug Transfer Device Market Size was valued at USD 2 Billion in 2022 and is projected to grow from USD 2.3 Billion in 2023 to USD 0.9 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 17.7% during the forecast period (2023 - 2032). Strict restrictions and standards for handling dangerous pharmaceuticals, as well as an increase in drug approvals and clinical trials are the key market drivers enhancing the market growth.

Closed System Drug Transfer Device Market


Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Closed System Drug Transfer Device Market Trends



  • The growing usage of CSTDs to address the side effects of cytotoxic and antineoplastic medicines is propelling market growth.


Market CAGR for Closed System Drug Transfer Device (CSTD) is being driven by the growing usage of CSTDs to address the side effects of cytotoxic and antineoplastic medicines. Antineoplastic medicines are commonly utilized in cancer treatment and are considered dangerous drugs. Healthcare workers who prepare, transport, distribute, administer (pre- and post-administration), and dispose of these medications are especially vulnerable. The National Institute for Occupational Safety and Health (NIOSH) suggests using CSTDs to eliminate the negative effects of exposure to hazardous compounds that escape from the system during drug preparation and administration. CSTDs operate as a barrier, preventing pollutants from entering and transferring from the atmosphere to the sterile environment. Because of these benefits, CSTDs are increasingly being employed in healthcare institutions to combat the negative effects of dangerous medications.


Chemotherapy, a popular cancer treatment, employs one or more antineoplastic medications to kill abnormal cells in patients. The use of closed system transfer devices (CSTDs) in conjunction with other safety measures including gloves, gowns, masks, and vented preparation hoods is an effective way to enhance safety when preparing, transporting, giving, and disposing of hazardous pharmaceuticals. The demand for CSTDs is predicted to rise in the coming years due to the rising incidence of cancer and the increased use of chemotherapy therapies.


Oncology drug research is currently a high priority for pharmaceutical corporations. Advances in cancer biology and therapeutic techniques have resulted in an increase in medication applications and approvals. The target patient group is likely to grow as the number of indications for previously approved cancer medications expands, boosting the consumption of risky oncology drugs. Additionally, new cancer discoveries will lead to more treatment options and raised safety concerns for novel medications. Innovation in oncology drug development is also encouraged by recent gains in clinical drug development brought about by improvements in the molecular understanding of cancer and corresponding focused pharmacological therapy, as well as by the need to quickly bring viable medications to market. The need for safety measures like CSTDs is rising as a result of the rising number of cancer medication approvals; this is anticipated to fuel market expansion. The rising occurrence of cancer is one factor driving the growth of the Closed System Drug Transfer Device (CSTD) Market. Cancer is one of the major causes of mortality worldwide, according to the World Health Organization, and the number of cancer cases is predicted to climb further in the future years. As a result, there is an increasing demand for safe and effective cancer drug delivery methods.


CSTDs are intended to prevent hazardous medications from escaping into the environment, thereby safeguarding healthcare staff and patients from exposure to these substances. With the rising occurrence of cancer, so is the demand for CSTDs. Equashield, a leading maker of CSTDs, for example, has witnessed an increase in demand for its products as a result of the COVID-19 pandemic, which has emphasized the need of drug safety and infection control in healthcare settings. Overall, rising cancer prevalence is driving demand for CSTDs, making it a key driver of market growth..


Closed System Drug Transfer Device Market Segment Insights


Closed System Drug Transfer Device Type Insights


The Market segmentation of Closed System Drug Transfer Device, based on type includes barrier-type, filtration-type. The barrier-type market grew significantly in the barrier-type category in 2022, and this trend is likely to continue during the forecast period due to the ease of use and lesser risk of contamination. However, filtration-type devices were the fastest expanding in 2022 due to their ease of use and safety.


Figure1  Closed System Drug Transfer Device (CSTD) Market, by Delivery, 2022 & 2032 (USD Billion)
Closed System Drug Transfer Device (CSTD) Market, by Delivery, 2022 & 2032


Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Closed System Drug Transfer Device Delivery Insights


The Closed System Drug Transfer Device Market segmentation, based on Delivery, includes closed bag/line access devices, closed vial access devices, closed syringe safety devices. Closed vial access devices category held the biggest market share in 2022, because oncology nurses are increasingly using CSTD products and vial access devices to transport hazardous medications from packaging vials to the infusion bag or the patient. However, the closed syringe safety devices category grew at the fastest rate over the forecast period, owing to benefits such as needle-free drug transfer, product introductions, and safety.


Closed System Drug Transfer Device Regional Insights


By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. In 2022, North America held the largest market share. The increase is ascribed to steps done by the US Food and Drug Administration and other North American regulatory authorities to enhance patient safety, as well as an increase in the number of oncology drug approvals in the region. Furthermore, the growing prevalence of chronic diseases in the North American region contributes to the expansion of the closed system transfer devices market.


Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 2  CLOSED SYSTEM DRUG TRANSFER DEVICE MARKET SHARE BY REGION 2022 (USD Billion)
CLOSED SYSTEM DRUG TRANSFER DEVICE (CSTD) MARKET SHARE BY REGION 2022


Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Europe Closed System Drug Transfer Device Market accounts for the second-largest market share due to increasing prevalence of cancer, the implementation of CSTDs in healthcare facilities, and the presence of important market competitors. Cancer is very common in Europe. Further, the German Closed System Drug Transfer Device Market held the largest market share, and the UK Closed System Drug Transfer Device (CSTD) Market was the fastest growing market in the European region


The Asia-Pacific Closed System Drug Transfer Device Market is expected to grow at the fastest CAGR from 2023 to 2032. This is because of the region's increased cancer prevalence in developing and impoverished countries. Moreover, China’s Closed System Drug Transfer Device (CSTD) Market held the largest market share, and the Indian Closed System Drug Transfer Device (CSTD) Market was the fastest growing market in the Asia-Pacific region.


Closed System Drug Transfer Device Key Market Players& Competitive Insights


Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Closed System Drug Transfer Device (CSTD) Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Closed System Drug Transfer Device (CSTD)industry must offer cost-effective items.


Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Closed System Drug Transfer Device (CSTD) industry to benefit clients and increase the market sector. In recent years, the Closed System Drug Transfer Device (CSTD) industry has offered some of the most significant advantages to medicine. Major players in the Closed System Drug Transfer Device (CSTD) Market, including Becton, Dickinson, and Company (US), ICU Medical (US), B. Braun Melsungen (Germany), and JMS (Japan) and others, are attempting to increase market demand by investing in research and development operations.


Braun is a German manufacturer of medical and pharmaceutical equipment with offices and production facilities spread over more than 60 nations and over 63,000 employees ly. Its headquarters are in Melsungen, which is in the heart of Germany. The Braun family still owns the company, which was formed in 1839. In December 2021, B. Braun Medical Inc., a well-known provider of closed system transfer devices, has announced the availability of the OnGuard 2 CSTD in the United States. All of OnGuard's current features are included in OnGuard 2, which also includes updated components and better functionality to make it more user-friendly. OnGuard 2 is the market leader in STD air-cleaning technology and was tested for vapour containment with genuine dangerous drugs.

ICU Medical, Inc. is a  firm headquartered in San Clemente, California. ICU Medical solutions are intended to safeguard healthcare personnel from infectious diseases and dangerous medications by preventing bloodstream infections. Intravenous treatment (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous medication handling devices and systems, sensor catheters, needle-free closed blood sampling systems, and hemodynamic monitoring systems are all part of the ICU Medical product line. September 2021, Smiths Group plc. and ICU Medical, Inc. announced that ICU Medical bought Smiths Medical division in a more beneficial transaction than Smiths Medical's earlier proposed sale to Trulli Bidco Limited. Smiths Medical is a company that sells syringes, ambulatory infusion devices, vascular access tools, and vital care items. The existing businesses of ICU Medical and Smiths Medical will be integrated as part of this transaction to build a premier infusion treatment firm with estimated pro forma revenue of about USD 2.5 billion.


Key Companies in the Closed System Drug Transfer Device market include



  • Equashield (US)

  • Simplivia Healthcare (Israel)

  • Corvida Medical (US)

  • Yukon Medical (US)

  • CODAN Medizinische Geräte (Germany)

  • VICTUS (US)

  • Caragen (US)


Closed System Drug Transfer Device (CSTD)Industry Developments


May 2022, Pulse NeedleFree Systems has created a needle-free livestock vaccination equipment disposable series. The product combines the advantages of needle-free technology with the convenience of plug-and-play operation at a price comparable to conventional syringes and needles.


March 2020, BD (Becton, Dickinson and Company) has announced the release of its new CSTD, the BD Intelliport System, which is intended to assist healthcare personnel in the safe and correct preparation and administration of hazardous medications.


June 2019, Pfizer, Inc. sold the Hospira Infusion Systems business to ICU Medical, Inc., which includes the development and manufacture of CSTDs. This acquisition enhanced ICU Medical's product portfolio and improved its position in the CSTD industry.


Closed System Drug Transfer Device Market Segmentation


Closed System Drug Transfer Device Type Outlook



  • Barrier-Type

  • Filtration-Type


 Closed System Drug Transfer Device Delivery Outlook



  • Closed Bag/Line Access Devices

  • Closed Vial Access Devices

  • Closed Syringe Safety Devices


Closed System Drug Transfer Device Regional Outlook



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America



Report Scope:

Closed System Drug Transfer Device (CSTD) Report Scope
Report Attribute/Metric Details
Market Size2022 USD 2Billion
Market Size 2023 USD 2.3Billion
Market Size 2032 USD 0.9 Billion
Compound Annual Growth Rate (CAGR) 17.7% (2023-2032)
Base Year 2022
Market Forecast Period 2023-2032
Historical Data 2018- 2022
Market Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered Type, Delivery, and Region
Geographies Covered North America, Europe, AsiaPacific, and the Rest of the World
Countries Covered The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled Becton, Dickinson, and Company (US), ICU Medical (US), B. Braun Melsungen (Germany), and JMS (Japan)
Key Market Opportunities Increased use of CSTDs in additional therapeutic areas
Key Market Dynamics Increasing the usage of CSTDs to counteract the negative effects of cytotoxic and antineoplastic medicines




Frequently Asked Questions (FAQ) :

The  Closed System Drug Transfer Device (CSTD) Market size was valued at USD 2 Billion in 2022.

The  market is projected to grow at a CAGR of 17.7% during the forecast period, 2023-2032.

The key players in the market are Becton, Dickinson, and Company (US), ICU Medical (US), B. Braun Melsungen (Germany), and JMS (Japan).

The barrier-type category dominated the market in 2022.

The Closed vial access devices had the largest share in the  market.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major playersÔÇÖ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid